Amylin Pharmaceuticals, Inc. (AMLN: Quote) announced new clinical data from the European Exenatide or EUREXA study that showed treatment with BYETTA injection resulted in greater glycemic durability and overall glycemic control than Amaryl in patients with type 2 diabetes uncontrolled on metformin alone.
The company also noted that patients treated with BYETTA have experienced reductions in body weight and fewer hypoglycemic events.
The company said these clinical study findings are being presented at the 2012 ADA/The Lancet Symposium at the 72nd Scientific Sessions of the American Diabetes Association in Philadelphia and will be published in the diabetes-themed issue of The Lancet.
Click here to receive FREE breaking news email alerts for Amylin Pharmaceuticals Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com